Breaking News
October 19, 2018 - URMC researchers discover new approach to deliver therapeutics to the brain
October 19, 2018 - Middlemen suppliers can increase drug prices and hospital bills, say Johns Hopkins researchers
October 19, 2018 - $11 million NIH grant for Clemson University helps launch new center for musculoskeletal research
October 19, 2018 - A new approach identified to control Zika virus, dengue fever
October 19, 2018 - Head Blows Without Concussion May Not Damage Brain, Study Claims
October 19, 2018 - US opioid use not declined, despite focus on abuse and awareness of risk
October 19, 2018 - Next-generation RNA sequencing technology sheds new light on human mitochondrial diseases
October 19, 2018 - UT Southwestern biochemist receives 2019 Breakthrough Prize in Life Sciences for innate immunity discovery
October 19, 2018 - The immune system also plays a key role in day-to-day function of healthy organs
October 19, 2018 - New tool may reveal how the brain structure impacts brain activity, human behavior
October 19, 2018 - Trump Administration announces ‘Winning on Reducing Food Waste’ initiative
October 19, 2018 - For-profit nursing home residents more likely to experience health issues caused by substandard care
October 19, 2018 - Incidence of stroke has risen steadily among marijuana users, show studies
October 19, 2018 - Conceptual framework proposed to examine role of exercise in multiple sclerosis
October 19, 2018 - Near infrared spectroscopy technique for accurate evaluation of chondral injuries
October 19, 2018 - Scientists receive $5.1 million grant to develop stem cell-based therapy for blinding retinal conditions
October 19, 2018 - Shorter physician encounters associated with antibiotic prescribing
October 19, 2018 - In the Spotlight: Enjoying research and exploring opportunities
October 19, 2018 - Physical activity lowers cardiovascular mortality risk in frail older adults
October 19, 2018 - New imaging tool helps visualize how sound-induced vibrations travel through the ear
October 19, 2018 - Key insights into the application, production of bioactive materials
October 19, 2018 - New urea sorbent could speed up the development of wearable artificial kidney
October 19, 2018 - Intensive care patients’ muscles less able to use fats for energy
October 19, 2018 - FDA Advisory Committee Recommends Approval of Dsuvia for the Treatment of Moderate-to-Severe Acute Pain
October 19, 2018 - 48,XXXY syndrome – Genetics Home Reference
October 19, 2018 - Physical exercise improves the elimination of toxic proteins from muscles
October 19, 2018 - How a new system improved wait times for Stanford kidney transplant patients
October 19, 2018 - Nutrition has bigger positive impact on bone mass and strength than exercise
October 19, 2018 - Study finds lack of progress in media representation of nurses over last 20 years
October 19, 2018 - Many people have trouble understanding differences between OCD and OCPD
October 19, 2018 - New family planning app found to be as effective as modern methods
October 19, 2018 - Gastric Banding, Metformin Similar for Improving Glycemia
October 19, 2018 - Physiologist publishes findings on the role of the protein titin in muscle contraction
October 19, 2018 - What digital health companies need to do to succeed
October 19, 2018 - N. Carolina Sees Alarming Spike in Heart Infections Among Opioid Users
October 19, 2018 - Video monitoring of TB therapy works well in urban and rural areas
October 19, 2018 - Determining acid-neutralizing capacity for OTC antacids
October 19, 2018 - Males who spend more time taking care of kids have greater reproductive success
October 18, 2018 - Study to explore bioethics of brain organoids
October 18, 2018 - Environmental conditions may drive development of multiple sclerosis
October 18, 2018 - Genetically modifying zebrafish provides more accurate disease models
October 18, 2018 - Purdue Pharma, Eisai announce positive topline results from Phase 3 study of lemborexant
October 18, 2018 - 5 Strength-Training Mistakes to Avoid
October 18, 2018 - Immune system’s balancing act keeps bowel disease in check
October 18, 2018 - Anti-inflammatory drug effective for treating lymphedema symptoms | News Center
October 18, 2018 - Keeping Your Voice Young
October 18, 2018 - One-time universal screening recommended to tackle increase in hepatitis C
October 18, 2018 - Researchers to develop new stem cell-based strategies for treating vision disorders
October 18, 2018 - Detecting epigenetic signature may help people stay ahead of inflammatory bowel disease
October 18, 2018 - Understanding AFib: Slowing down the dancing heart
October 18, 2018 - Using NMR to Reduce Fraud
October 18, 2018 - New automated model identifies dense breast tissue in mammograms
October 18, 2018 - Mysterious polio-like illness baffles medical experts while frightening parents
October 18, 2018 - Cases of Acute Flaccid Myelitis on the rise across U.S.
October 18, 2018 - Dietary fiber reduces brain inflammation during aging
October 18, 2018 - New tool could help prioritize recovery efforts for the poorest hit by natural disasters
October 18, 2018 - Hundreds of dietary supplements shown to contain unapproved drugs
October 18, 2018 - Active Pharmaceuticals ID’d in >700 Dietary Supplements
October 18, 2018 - Cell death protein also damps inflammation
October 18, 2018 - AI pathology diagnostic tool developed using deep learning technology from Olympus
October 18, 2018 - Health Highlights: Oct. 15, 2018
October 18, 2018 - Largest study of ‘post-treatment controllers’ reveals clues about HIV remission
October 18, 2018 - Bad Blood in Silicon Valley: A conversation with John Carreyrou
October 18, 2018 - ANTRUK’s Annual Lecture sends out message on shortage of funds for antibiotic research
October 18, 2018 - NAM special publication outlines steps to ensure interoperability of health care systems
October 18, 2018 - Novel method uses just a drop of blood to monitor effect of lung cancer therapy
October 18, 2018 - New blood test could spare cancer patients from unnecessary chemotherapy
October 18, 2018 - Training young researchers to work with data volumes arising in the health sector
October 18, 2018 - New Metrohm IC method is reliable and convenient to use for zinc oxide assay
October 18, 2018 - Global AIDS, TB fight needs more money: health fund
October 18, 2018 - Understanding the forces that cause sports concussions
October 18, 2018 - Research points to new target for treating periodontitis
October 18, 2018 - New tool improves assessment of postpartum depression symptoms
October 18, 2018 - From Biopsy to Diagnosis
October 18, 2018 - Sexual harassment and assault linked to worse physical/mental health among midlife women
October 18, 2018 - Stumped by medical school? A Q&A with a learning specialist
October 18, 2018 - Report predicts life expectancy in 2040, Spain comes out on top
October 18, 2018 - Self-lubricating condoms may help raise condom usage
October 18, 2018 - Targeting immune checkpoints in microglia could reduce out-of-control neuroinflammation
October 18, 2018 - Study finds changes in antiepileptic drug metabolism during different trimesters of pregnancy
New drug for migraine in the pipeline

New drug for migraine in the pipeline

image_pdfDownload PDFimage_print

According to a pilot study results released yesterday (17th of April 2018), a new drug may help provide relief to people with migraine that is unsuccessfully treated with the currently available drugs.

Researchers have developed Erenumab, which belongs to a human monoclonal antibody class of drugs that can block calcitonin gene-related peptide (CGRP). This CGRP is a molecule that can transmit the signals of pain during an attack of migraine. According to experts, blocking CGRP can prevent the onset of a migraine attack before it even starts. Researchers have found that a long lasting injection of the new drug can prevent the onset of the migraine attacks by blocking the CGRP.

Migraine. Image Credit: svershinsky / Shutterstock

Migraine. Image Credit: svershinsky / Shutterstock

Migraine affects over thirty-seven million Americans according to the American Headache Society. Around 4 million Americans suffer from chronic migraine which means they have attacks of debilitating headaches for at least 10 to 14 days in a month. Treatment includes over the counter pain medications such as ibuprofen and also stronger medications such as sumatriptan and ergotamine. Migraine is essentially caused by dilatation of the blood vessels around the brain that leads to intense headache, nausea and dizziness. Sumatriptan and ergotamine help to constrict these blood vessels and thus ease the pain. These drugs however may not be effective in all people with migraine.

Lead author of the study Dr. Peter Goadsby, professor of neurology at Kings College London, UK and University of California, San Francisco said that this is the first time a drug can effectively prevent the attacks of migraine. He said that this drug will change the treatment for people who do not respond to the traditional treatments available for migraine.

The study involved adults with chronic migraine who had four to fourteen attacks of migraine per month. Those with over 15 attacks per month and who have failed to respond to treatment with drugs such as topiramate, propranolol and amitriptyline were included in this study. The new drug was used among the participants.

This study included 246 participants who were given 140 mg of erenumab or a placebo once in a month for three months. Of these 39 percent had earlier been treated unsuccessfully with two other anti-migraine medications, 38 percent were earlier treated with three other medications and 23 percent were unsuccessful with even four medications. At baseline the participants had an average of nine migraine headaches per month and had to use a drug to curb an acute attack at least five times a month.

The results revealed that in over a third of the study participants the monthly migraine attacks were reduced by more than half. Patients experienced a three times more chance of reduced migraine days by 50 percent after being treated with the new drug for three months compared to those who were treated using a placebo. The number of days that the patients needed to stop the attacks of migraine were also significantly reduced in these patients. Number of days with headaches also reduced substantially. None of the patients who were put on the new drug Erenumab had to discontinue the drug because they experienced side effects. The study was supported by Novartis Pharma AG.

The makers hope that this new drug would get a green light from the Food and Drug Administration this year. The cost of the drug is estimated to be around $10,000 annually at present. The study results would be presented at the American Academy of Neurology’s 70th Annual Meeting in Los Angeles, between April 21st and 27th, 2018.

Source:

https://www.aan.com/PressRoom/Home/PressRelease/1641

Tagged with:

About author

Related Articles